Authors: Elalfy H, Besheer T, El-Mesery A, El-Gilany AH, Hewidy AA PMID: 33590901 PMCID: PMC8014583 DOI: 10.1002/jmv.26880 Abstract This trial compared the rate and time of viral clearance in subjects receiving a combination of nitazoxanide, ribavirin, and ivermectin plus Zinc versus those receiving supportive treatment. This non-randomized controlled trial included 62 patients on the triple [...]

Authors: Zarehoseinzade E, Allami A, Ahmadi M, Bijani B PMID: 34169042 PMCID: PMC8214036 DOI: 10.47176/mjiri.35.30 Abstract Background: There is controversy about the efficacy of 5-alpha-reductase inhibitors in COVID-19 patients. Some assumed that finasteride might be a risk factor for deterioration and others proposed it as a possible adjunct treatment for moderate [...]

Authors: Wambier CG, Lin EM, Cadegiani FA, Goren A, Nau GJ PMID: 33633920 PMCID: PMC7899267 DOI: 10.7759/cureus.13492 Abstract Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into type II pneumocytes is dependent on a modification of viral spike proteins by transmembrane protease serine 2 (TMPRSS2) expressed on the surface of human cells. [...]

Authors: Thimmulappa RK, Mudnakudu-Nagaraju KK, Shivamallu C, Bhojraj S. PMID: PMC7899028 doi: 10.1016/j.heliyon.2021.e06350 Abstract Coronavirus disease-19 (COVID-19), a devastating respiratory illness caused by SARS-associated coronavirus-2 (SARS-CoV-2), has already affected over 64 million people and caused 1.48 million deaths, just 12 months from the first diagnosis. COVID-19 patients develop serious complications, including severe pneumonia, acute respiratory [...]

Authors: Hoertel N, Sanchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A doi: https://doi.org/10.1038/s41380-021-01021-4 Abstract A prior meta-analysis showed that antidepressant use in major depressive disorder was associated with reduced plasma levels of several pro-inflammatory mediators, which have been associated with severe COVID-19. Recent studies also suggest that several antidepressants [...]

Authors: Seftel D, Boulware DR PMID: 33623808 PMCID: PMC7888564 DOI: 10.1093/ofid/ofab050 Abstract We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 [...]

Authors: Cadegiani FA, McCoy J, Wambier CG, Goren A PMID: 33643746 PMCID: PMC7885746 DOI: 10.7759/cureus.13047 Abstract Background and objective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and subsequent infectivity are mediated by androgens and the androgen receptors through the regulation of transmembrane protease, serine 2 (TMPRSS2). Androgenetic alopecia (AGA) [...]

Authors: Saeedi-Boroujeni A, Mahmoudian-Sani MR. PMID: Abstract SARS-CoV-2 is a betacoronavirus causing severe inflammatory pneumonia, so that excessive inflammation is considered a risk factor for the disease. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress [...]

Authors: Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH et al. doi: https://doi.org/10.1101/2021.01.26.21250494 Abstract Background Evidence suggests the role of an inflammatory storm in COVID-19 complications. Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease. Methods We performed a randomized, double-blind trial [...]

Authors: Jena AB, Kanungo N, Nayak V, Chainy GB. PMID: PMC8043087 DOI: 10.1038/s41598-021-88218-3 Abstract The recent outbreak of the coronavirus (SARS-CoV2) is an unprecedented threat to human health and society across the globe. In this context, development of suitable interventions is the need of the hour. The viral spike protein (S Protein) and the cognate [...]